Rexahn wins US patent for oncology-based compounds

The patent, which covers the process for the preparation of the compounds and their pharmaceutical composition, includes RX-5902, a p68 helicase inhibitor, available in oral dosage form.

RX-5902, in addition to exhibiting antitumor properties in several types of tumors, possess strong anti-proliferative activity against known anti-cancer drug-resistant cancer cells, and a synergistic effect with known anti-cancer drugs.

Rexahn Pharmaceuticals president Rick Soni said with the issuance of the patent, the company has gained the intellectual property protection for Quinoxalinyl-piperazine derivatives.

"This patent is significant step forward in the development of RX-5902, and further strengthens our overall global intellectual property position in oncology," Soni added.

Previously, patents were awarded for quinoxalinyl-piperazine compounds in Europe, Australia, Canada and Mexico, the company said.